Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2008 Jan 3;9(2):130–138. [Article in French] doi: 10.1016/S1294-5501(07)88778-4

Immunité et vaccinations antivirales : exemple de la muqueuse respiratoire

Immunity and antiviral vaccinations. Example: the respiratory mucosa

F Denis 1,⁎, S Hantz 1, S Alain 1
PMCID: PMC7146774  PMID: 32288532

Abstract

Objective

As the mucosal surfaces of the respiratory tract represent a major portal of entry for most human viruses and many bacteria, they seem to be a critical component of the mammalian immunologic repertoire. Thus, vaccines stimulating this local immunity could represent an interesting approach to prevent these infections. After detailing the different mechanisms implied in this mucosal immunity, the aim of this study is to analyze the basis of such a vaccination and the different vaccines available to mucosal respiratory tract use.

Mucosal immunity

The major antibody isotype in external secretions is secretory immunoglobin A (S-IgA); the role of IgM (S-IgM) and IgG (S-IgG) are actually questionned. It is, however, interesting that the major effector cells in the mucosal surfaces are not IgA B cells, but T lymphocytes that may represent up to 80% of the entire mucosal lymphoid cell population.

Immunoprophylaxis by the mucosal route

Passive antibodies were shown to protect against mucosal viral infections, such as those caused by RSV, but very high quantities of passive antibodies are needed to restrict virus replication on mucosal surface.

In general, factors which favor development of mucosal antibody and cell mediated immune responses include the oral or respiratory immunization and the replicating nature of the vaccine agents. However, to date only a few vaccines have become available to mucosal respiratory tract use, and cold-adapted influenza virus vaccines is the only one available using nasal route. Other parenteral licensed vaccines have not been recommended for mucosal administration. Some of them have been experimentally used with nasal administration of replicating agents (varicella and measles vaccines) or non replicating agents (influenza inactivated vaccine), but have been found to induce a very low mucosal response.

Conclusion

Based on the experience with existing vaccines, the development of mucosal immunity or administration of vaccines via the mucosal route is clearly not a prerequisite today for control or prevention of most viral infectious respiratory diseases or diseases with respiratory tract as a route of contamination. But the example of live attenuated intranasal influenza vaccine inducing both systemic and local immune response without immunopathology, is promising for the future of the mucosal immunization against respiratory viral infections.

Key words: Mucosal vaccination, virus, respiratory tract, S-IgA, cold-adaptated influenza vaccines

Références

  • 1.Beytout J, Laurichesse H, Rey M. Vaccinations. Encycl Med Chir (Éditions Scientifiques et Médicales Elsevier SAS, Paris, droits réservés), Maladies infectieuses, 8-002-Q-10, 2001, 14 p.
  • 2.Dreffier C., Ramisse F., Alonso J.M. Immunoprophylaxie des infections respiratoires. Médecine/Sciences. 2004;20:999–1003. doi: 10.1051/medsci/20042011999. [DOI] [PubMed] [Google Scholar]
  • 3.Reynolds H.Y. Normal and defensive respiratory host defenses. In: Pennington J.E., editor. Respiratory infections. Raven Press; New York: 1994. pp. 1–33. [Google Scholar]
  • 4.Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006;6:148–158. doi: 10.1038/nri1777. [DOI] [PubMed] [Google Scholar]
  • 5.Bouvet J.P. Immunité des muqueuses. In: Mege J.L., Revillard J.P., Raould D., editors. Immunité et infection. Concepts immunopathologiques et perspectives thérapeutiques. Arnette; Paris: 1997. pp. 27–38. [Google Scholar]
  • 6.Denis F., Alain S., Hantz S. Vaccination antivirale et immunité muqueuse respiratoire : un concept séduisant pour des résultats encore décevants. Presse Med. 2005;34:1245–1253. doi: 10.1016/S0755-4982(05)84165-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ogra P.L., Faden H., Welliver R.C. Vaccination strategies for mucosal immune responses. Clin Microbiol Reviews. 2001;14:430–445. doi: 10.1128/CMR.14.2.430-445.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Belshe R.B., Maassab H.F., Mendelman P.M. Influenza Vaccine-Live S. In: Plotkin S.A., Orenstein W.A., editors. Vaccines”. Fourth Ed. Saunders; Philadelphia: 2004. pp. 371–388. [Google Scholar]
  • 9.Valdespino-Gomez J.L., De Lourdes Garcia-Garcia.F M., Fernandez-De-Castro J. Measles aerosol vaccination. Curr Top Microbiol Immunol, Springer-Verlag Berlin Heidelberg. 2006;304:165–193. doi: 10.1007/3-540-36583-4_10. [DOI] [PubMed] [Google Scholar]
  • 10.Brayden D.J., Baird A.W. Microparticle vaccine approaches to stimulate mucosal immunisation. Microbes and Infection. 2001;3:867–876. doi: 10.1016/s1286-4579(01)01445-9. [DOI] [PubMed] [Google Scholar]
  • 11.Bramwell V.W., Perrie Y. Particle delivery systems for vaccines. Critical ReviewsTM in Therapeutic Drug carrier systems. 2005;22:151–214. doi: 10.1615/critrevtherdrugcarriersyst.v22.i2.20. [DOI] [PubMed] [Google Scholar]
  • 12.Belshe R.B., Gruber W.C., Mendelman P.M. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent intranasal influenza virus vaccine. J Infect Dis. 2000;181:1133–1137. doi: 10.1086/315323. [DOI] [PubMed] [Google Scholar]
  • 13.Clements M.L., Betts R.F., Tierney E.L. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol. 1986;24:157–160. doi: 10.1128/jcm.24.1.157-160.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Greenbaum E., Engelhard D., Levy R. Mucosal (S-Ig A) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactived trivalent anti-influenza vaccine. Vaccine. 2004;22:2566–2577. doi: 10.1016/j.vaccine.2003.12.018. [DOI] [PubMed] [Google Scholar]
  • 15.Cox R.J., Brokstad K.A., Ogra P. Influenza virus : immunity and vacccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol. 2004;59:1–15. doi: 10.1111/j.0300-9475.2004.01382.x. [DOI] [PubMed] [Google Scholar]
  • 16.Powers D.C., Murphy B.R., Fries L.F. Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J Am Geriatr Soc. 1992;40:163–167. doi: 10.1111/j.1532-5415.1992.tb01938.x. [DOI] [PubMed] [Google Scholar]
  • 17.Treanor J.J., Betts R.F. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Vaccines. 1998;16:1756–1760. doi: 10.1016/s0264-410x(98)00136-4. [DOI] [PubMed] [Google Scholar]
  • 18.Van Ginkel F.W., Nguyen H.H., McGhee J.R. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerging Inf Dis. 2000;6:123–132. doi: 10.3201/eid0602.000204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.De Castro J.F., Bennett J.V., Rincon H.G. Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol) Vaccine. 2005;23:1079–1084. doi: 10.1016/j.vaccine.2004.08.018. [DOI] [PubMed] [Google Scholar]
  • 20.Cutts F.T., Clements C.J., Bennett J.V. Alternative routes of measles immunization: a review. Biologicals. 1997;25:323–328. doi: 10.1006/biol.1997.0103. [DOI] [PubMed] [Google Scholar]
  • 21.Kaul D., Ogra P. Mucosal responses to parenteral and mucosal vaccines. In: Plotkin S., Brown F., Horaud F., editors. Vol. 95. Dev Biol Stand Basel Karger; 1998. pp. 141–146. (Pre clinical development of new vaccines). [PubMed] [Google Scholar]
  • 22.Simasathien S., Migasena S., Bellini W. Measles vaccination of Thai infants by intranasal and subcutaneous routes: possible interference from respiratory infections. Vaccine. 1997;15:329–334. doi: 10.1016/s0264-410x(97)00104-7. [DOI] [PubMed] [Google Scholar]
  • 23.Cradock-Watson J.E., Macdonald H., Ridehalgh M.K. Specific immunoglobulin responses in serum and nasal secretions after the administration of attenuated rubella vaccine. J Hyg. 1974;73:127–141. doi: 10.1017/s0022172400023925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ogra P.L., Kerr-Grant D., Umana G. Antibody response in serum and nasopharynx after naturally acquired and vaccine induced infection with rubella virus. N Engl J Med. 1971;285:1333. doi: 10.1056/NEJM197112092852401. [DOI] [PubMed] [Google Scholar]
  • 25.Ichinohe T., Watanabe I., Tao E. Protection against influenza virus infection by intranasal vaccine with surf clam microparticules (SMP) as an adjuvant. J Med Virol. 2006;78:954–963. doi: 10.1002/jmv.20647. [DOI] [PubMed] [Google Scholar]
  • 26.Lee J.S., Poo H., Han D.P. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol. 2006;80:4079–4087. doi: 10.1128/JVI.80.8.4079-4087.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Gaudelus J. Vaccination anti-virus respiratoire syncitial. Virologie. 2003;7:S170–S176. [Google Scholar]
  • 28.Hall C.B., Walsh E.E., Long C.E. Immunity to and frequency of reinfection with respiratory syncitial virus. J Infect Dis. 1991;163:693–698. doi: 10.1093/infdis/163.4.693. [DOI] [PubMed] [Google Scholar]
  • 29.Karron R.A., Wright P.F., Belshe R.B. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005;191:1093–1104. doi: 10.1086/427813. [DOI] [PubMed] [Google Scholar]
  • 30.Pothier P., Agnello D., Manoha-Bourgeois G. Physiopathologie des infections à virus respiratoire syncitial. Virologie. 2003;7:S145–S155. [Google Scholar]
  • 31.Razafimahefa H., Lacaze-Masmonteil T. Infection à virus respiratoire syncitial : facteurs de risque et immunothérapie passive. Virologie. 2003;7:5162–5169. [Google Scholar]
  • 32.Falcone V., Mihm D., Neumann-Haetelin D. Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant Streptococcus gordonïï surface-displaying a domain of viral glycoprotein G. FEMS Immunol Med Microbiol. 2006;48:116–122. doi: 10.1111/j.1574-695X.2006.00130.x. [DOI] [PubMed] [Google Scholar]
  • 33.Dell K., Koesters R., Linnebacher M. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine. 2006;24:2238–2247. doi: 10.1016/j.vaccine.2005.11.060. [DOI] [PubMed] [Google Scholar]
  • 34.Van Cott J.L., Prada A.E., Mc Neal M. Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT (R192G) or orally with live rhesus Rotavirus vaccine candidates. J Virol. 2006;80:4949–4961. doi: 10.1128/JVI.80.10.4949-4961.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Bout D., Mevelec M.M., Velge-Roussel F. Vaccins muqueux. In: Cohen G.N., Sansonetti P., editors. « La vaccinologie ». Elsevier; Paris: 2002. pp. 55–65. [Google Scholar]
  • 36.Ferro V.A., Carter K.C. Mucosal immunisation : successful approaches to targeting different tissues. Methods. 2006;38:61–64. doi: 10.1016/j.ymeth.2005.11.004. [DOI] [PubMed] [Google Scholar]
  • 37.Ogra P.L., Fishaut M., Gallagher M.R. Viral vaccination via the mucosal routes. Rev Infect Dis. 1980;2:352–369. doi: 10.1093/clinids/2.3.352. [DOI] [PubMed] [Google Scholar]
  • 38.Plotkin S.A. Immunologic correlates to protection induced by vaccination. Pediatr Infect Dis. 2001;20:63–75. doi: 10.1097/00006454-200101000-00013. [DOI] [PubMed] [Google Scholar]
  • 39.Système immunitaire muqueux et vaccination. In Vaccinations. Actualisations et perspectives. Inserm, Paris, 1999, p. 161-97.
  • 40.Iijima H., Takahashi I., Kiyono H. Mucosal immune network in the gut for the control of infectious diseases. Rev Med Virol. 2001;11:117–133. doi: 10.1002/rmv.307. [DOI] [PubMed] [Google Scholar]

Articles from Antibiotiques (Paris, France : 1999) are provided here courtesy of Elsevier

RESOURCES